Developing pathogen reduction technologies for RBC suspensions

Vox Sanguinis

Volumn 100, Issue 1, 2011, Pages 112-121

  Wagner, S J ^a  

^a HOLLAND LABORATORY   (United States)

Author keywords

Component storage; Pathogen reduction; Red cell; Transfusion; Transmissible infections

Indexed keywords

ALKYLATING AGENT; BENZOPORPHYRIN DERIVATIVE; HYPERICIN; INACTINE; MEROCYANINE; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; S 303; THIAZOLE ORANGE; THIOPYRYLIUM; UNCLASSIFIED DRUG;

BLOOD STORAGE; DRUG MECHANISM; ERYTHROCYTE PRESERVATION; INFECTION CONTROL; OXIDATIVE STRESS; PATHOGEN REDUCTION; PRIORITY JOURNAL; REVIEW; SAFETY; VIRUS INFECTION;

ALKYLATING AGENTS; BLOOD SAFETY; DISEASE TRANSMISSION, INFECTIOUS; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HUMANS; NUCLEIC ACIDS; PHOTOSENSITIZING AGENTS;

EID: 78650395330     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01386.x     Document Type: Review

References (57)

1. Dodd RY: Current risk for transfusion transmitted infections. Curr Opin Hematol 2007; 14:671-676
2. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49(Suppl 2):1S-29S
3. Pelletier JP, Transue S, Snyder EL: Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19:205-242
4. Bryant BJ, Klein HG: Pathogen inactivation. The definitive safeguard for the blood supply. Arch Pathol Lab Med 2007; 131:719-733
5. Solheim BG: Pathogen reduction of blood components. Transfus Apher Sci 2008; 39:75-82
6. Wagner SJ, Friedman LI, Dodd RY: Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Transfus Med Rev 1991; 1:18-32
7. Goodrich RP, Custer B, Keil S, et al. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010: doi.
8. Weimer T, Streichert S, Watson C, et al. High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation. Transfusion 2001; 41:1500-1504
9. Eder AF, Kennedy JM, Dy BA, et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554-1563
10. Kanofsky JR: Quenching of singlet oxygen by human RBC ghosts. Photochem Photobiol 1991; 53:93-99
11. Redmond RW, Kochevar IE: Spatially resolved cellular responses to singlet oxygen. Photochem Photobiol 2006; 82:1178-1186
12. O'Brien JM, Gaffney DK, Wang TP, et al. Merocyanine 540-sensitized photoinactivation of enveloped viruses in blood products: site and mechanism of phototoxicity. Blood 1992; 80:277-285
13. Cole M, Stromberg RR, Friedman LI, et al. Photochemical inactivation of virus in RBCs. Transfusion 1989; 29:42S (abstract S145)
14. Sieber F, O'Brien JM, Gaffney DK: Antiviral effects of photosensitizing merocyanine dyes: implications for transfusion and bone marrow transplantation. Semin Hematol 1992; 29:79-87
15. North J, Neyndorff H, King D, et al. Viral inactivation in blood and RBC concentrates with benzoporphyrin derivative. Blood Cells 1992; 18:129-140
16. Valeri CR, Ragno G, MacGregor H, et al. The effect of disinfection on viability and function of baboon red blood cells. Photochem Photobiol 1997; 65:446-450
17. Prince AM, Pascual D, Meruelo D, et al. Strategies for evaluation of enveloped virus inactivation in RBC concentrates using hypericin. Photochem Photobiol 2000; 71:188-195
18. Howorowitz B, Williams B, Rywkin S, et al. Inactivation of viruses in blood with aluminum phthalocyanine derivatives. Transfusion 1991; 31:102-108
19. Ben-Hur E, Rywkin S, Rosenthal I, et al. Virus inactivation in RBC concentrates by photosensitization with phthalocyanines: protection of RBCs by not of vesicular stomatitis virus with a water-soluble analogue of vitamin E. Transfusion 1995; 35:401-406
20. Rywkin S, Ben-Hur E, Reid ME, et al. Selective protection against IgG binding to RBCs treated with phthalocyanines and red light for virus inactivation. Transfusion 1995; 35:414-420
21. Ben-Hur E, Chan WS, Yim Z, et al. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC4 and red light. Dev Biol (Basel) 2000; 102:149-156
22. Wagner SJ, Storry JR, Mallory DA, et al. RBC membrane alterations associated with virucidal methylene blue phototreatment. Transfusion 1992; 33:30-36
23. Wagner SJ, Robinette D, Storry J, et al. Differential sensitivity of viruses in RBCs to methylene blue photosensitization. Transfusion 1994; 34:521-526
24. Skripchenko A, Robinette D, Wagner SJ: Comparison of methylene blue and methylene violet for photoinactivation of intracellular and extracellular virus in RBC suspensions. Photochem Photobiol 1997; 65:451-455
25. Wagner SJ, Skripchenko A, Robinette D, et al. Preservation of RBC properties after virucidal phototreatment with dimethylmethylene blue. Transfusion 1998; 38:729-737
26. Wagner S, Skripchenko A, Thompson-Montgomery D: Use of a flow-cell system to investigate virucidal dimethylmethylene blue phototreatment in two RBC additive solutions. Transfusion 2002; 42:1200-1205
27. Wagner SJ, Skripchenko A, Thompson-Montgomery D: Quinacrine enhances vesicular stomatitis virus inactivation and diminishes hemolysis of dimethylmethylene blue phototreated cells. Photochem Photobiol 2002; 76:514-517
28. Besselink GAJ, van Engelenburg FAC, Korsten HG, et al. The band III ligand dipyridamole protects human RBCs during photodynamic treatment while extracellular virus inactivation is not affected. Transfusion 2002; 42:728-733
29. Ohulchanskyy TY, Gannon MK II, Ye M, et al. "Switched-on" flexible chalcogenopyrylium photosensitizers. changes in photophysical properties upon binding to DNA. J Phys Chem B 2007; 111:9686-9692
30. Wagner SJ, Skripchenko A, Cincotta L, et al. Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of RBC storage properties. Transfusion 2005; 45:752-760
31. Wagner SJ, Skripchenko A, Salata J, et al. Photoinactivation of Leishmania donovani infantum in RBC suspensions by a flexible thiopyrylium sensitizer. Vox Sang 2006; 91:178-180
32. Wagner SJ, Skripchenko A, Salata J, et al. Photoinactivation of Trypanosoma cruzi in RBC suspensions with thiopyrylium. Transfus Apher Sci 2007; 37:23-25
33. Skripchenko A, Balch A, Mackin A, et al. In vivo recovery and survival of RBCs after photodynamic treatment with thiopyrylium and red light using a canine model. Vox Sang 2007; 92:157-159
34. Akerman B, Tuite E: Single- and double-strand photocleavage of DNA by YO, YOYO and TOTO. Nucleic Acids Res 1996; 24:1080-1090
35. Skripchenko A, Wagner SJ, Thompson-Montgomery D, et al. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining RBC storage properties. Transfusion 2006; 46:213-219
36. Wagner SJ, Skripchenko A, Salata J, et al. Inactivation of Leishmania donovani infantum and Trypanosoma cruzi in RBC suspensions with thiazole orange. Transfusion 2008; 48:1363-1367
37. Tanirbergenov TB, Vasil'eva SV, Kostianovskii RG, et al. Characteristics of the mutagenic and toxic effects of ethylene imine and its oligomers. Comparative study in the automated SOS-chromotest system and in standard bacterial test systems. Genetika 1988; 24:763-765
38. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN 110 chemistry: preclinical studies. Transfusion 2002; 42:139-145
39. Chapman JR, Moore K, Butterworth BE: Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion 2003; 43:1386-1393
40. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase 1 clinical study. Transfusion 2002; 42:146-152
41. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in RBC concentrates using INACTINE™ PEN110 chemistry. Vox Sang 2002; 83:313-323
42. Mather T, Takeda T, Tassello J, et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion 2003; 43:1029-1037
43. Aytay S, Ohagen A, Busch MR, et al. Development of a sensitive PCR inhibition method to demonstrate HBV nucleic acid inactivation. Transfusion 2004; 44:476-484
44. Ohagen A, Gibaja V, Aytay S, et al. Inactivation of HIV in blood. Transfusion 2002; 42:1308-1317
45. Zavizion B, Serebryanik D, Serebryanik I, et al. Prevention of Yersinia enterocolitica, Psudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion 2003; 43:135-142
46. Zavizion B, Serebryanik D, Chapman J, et al. Inactivation of gram-negative and gram-positive bacteria in RBC concentrates using INACTINE PEN110 chemistry. Vox Sang 2004; 87:143-149
47. Zavizion B, Pereira M, de MeloJorge M, et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004; 44:731-738
48. Hoffmann GR, Freemer CS, Parente LA: Induction of genetic duplications and frameshift mutations in Salmonella typhimurium by acridines and acridine mustards: dependence on covalent binding of the mutagen to DNA. Mol Gen Genet 1989; 218:377-383
49. Rios JA, Hambleton J, Viele M, et al. Viability of RBCs prepared with S-303 pathogen inactivation treatment. Transfusion 2005; 46:1778-1786
50. Ciaravino V, Stassinopoulos A, Singh Y, et al. INTERCEPT red blood cells are not genotoxic or carcinogenic in a series of in vitro and in vivo tests. Blood 2002; 100(Suppl 1):143b (abstract 4055)
51. Dupuis K, Bernard K, Jones S, et al. Helinx® technology inactivates pathogens of emerging importance in red blood cell concentrates. Blood 2003; 102(Suppl):816a (abstract 3020)
52. Stassinopoulos A, Mababangloob RS, Dupuis KW, et al. Bacterial inactivation in leukoreduced PRBC treated with HELINX™. Transfusion 2000; 40(Suppl):38S (abstract S139-0401)
53. Cook D, Stassinopoulos A, Merrit J, et al. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303. Blood 1997; 90(Suppl):409a (abstract 1820)
54. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45:1739-1749
55. Stassinopoulos A, Schott MA, Castro GM, et al. Elimination of immunoreactivity of RBCs treated with a modified S-303 pathogen inactivation process. Blood 2004; 105(Suppl):738a (abstract 2703)
56. Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38:14-19
57. Goodrich RP, Doane S, Reddy HL: Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38:20-30